Mazdutide
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
Mazdutide is a once-weekly peptide that acts as a dual agonist at both the GLP-1 and glucagon receptors. It was originally developed from oxyntomodulin, a naturally occurring gut hormone, and is studied primarily in the context of weight management and type 2 diabetes.
It belongs to a newer generation of metabolic peptides that combine more than one receptor target. The idea is that pairing GLP-1’s appetite-suppressing effects with glucagon receptor activation may add complementary metabolic benefits beyond what a GLP-1-only agent provides.
Mazdutide has completed phase 3 trials in China, where it has been approved for chronic weight management and for glycemic control in type 2 diabetes. It is not approved by the FDA or the EMA, and much of the published clinical evidence to date comes from Chinese study populations.
How it works
GLP-1 receptor activation is commonly associated with reduced appetite, slower gastric emptying, and improved insulin secretion. Glucagon receptor activation is studied for a different set of effects — increased energy expenditure through thermogenesis and reduced fat accumulation in the liver. By engaging both pathways, mazdutide is designed to combine appetite suppression with a potential increase in the number of calories the body burns.
The relative contribution of each receptor to the overall effect is still being characterized, and long-term outcomes outside of trial settings remain an area of ongoing study.
Reported benefits
- Substantial body weight reduction reported across phase 2 and phase 3 trials
- Improved glycemic control (lower HbA1c) in type 2 diabetes studies
- Reductions in liver fat content reported in trial participants
- Studied effects on waist circumference, blood lipids, and blood pressure
These are reported and studied effects, not guaranteed outcomes.
Considerations & side effects
The most commonly reported side effects are gastrointestinal — nausea, vomiting, and diarrhea — which are consistent with the broader GLP-1 receptor agonist class and appear to be dose-dependent. In trials these were generally mild to moderate.
Because approval and most published data are concentrated in Chinese study populations, the profile in other populations and over longer time horizons is less well characterized. Mazdutide is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is mazdutide?
Mazdutide (also known by the development code IBI362) is a once-weekly dual agonist that activates both the GLP-1 and glucagon receptors, studied primarily for weight management and type 2 diabetes.
Is mazdutide FDA-approved?
No. Mazdutide has been approved by China's National Medical Products Administration (NMPA) for chronic weight management and for type 2 diabetes, but it is not approved by the FDA or the EMA.
How is mazdutide different from a GLP-1-only drug like semaglutide?
In addition to the GLP-1 receptor activity that curbs appetite, mazdutide also engages the glucagon receptor, which is studied for its role in increasing energy expenditure and reducing liver fat. Head-to-head data comparing it to GLP-1-only agents continues to emerge.
What is it studied for?
Clinical trials have focused on chronic weight management and glycemic control in type 2 diabetes, with reported effects also studied on liver fat, blood lipids, and blood pressure.
References
- Ji L, et al. Safety and efficacy of the GLP-1/glucagon dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity (phase 1b). ↗
- Ji L, et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nature Communications. ↗
- Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management. ↗
Related compounds
Triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase III clinical trials have demonstrated the highest weight loss of any investigational drug in its class.
Dual GLP-1 and glucagon receptor agonist. In clinical trials for obesity and metabolic dysfunction-associated steatohepatitis (MASH). Glucagon component enhances fat oxidation.
Long-acting amylin receptor agonist for weight management. Combined with semaglutide in CagriSema, showing up to 22.7% weight loss in Phase III trials.